EANS-News: SYGNIS Pharma AG / SYGNIS announces three months results of fiscal year 2011/2012

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

3-month report

Heidelberg (euro adhoc) - SYGNIS announces three months results of
fiscal year 2011/2012

• Financing secured until end of 2012
• Patient recruitment of AXIS Study is now finalised
• Patent rights for the KIBRA project further strengthened

Heidelberg, August 11, 2011 - SYGNIS Pharma AG (Frankfurt:
LIOK; ISIN DE000A1E9B74; Prime Standard) today reports its
financial results for the first quarter of the fiscal year 2011/2012
ended June 30, 2011.

Financials

• The net loss in the first quarter decreased to EUR-1.3 million
(EUR-2.3 million Q1 2010/2011). Financial result was EUR0.7 million
(EUR0.1 million Q1 2010/2011).
• Total operating expenses for the first quarter were down at EUR2.2
million (EUR2.5 million Q1 2010/2011).
• Cash including marketable securities amounted to EUR4.8 million as of
June 30, 2011 (EUR13.1 million Q1 2010/2011).
• Mid June 2011, SYGNIS secured additional funds of EUR6.0 million through
the subordinated loan of dievini Hopp BioTech holding GmbH & Co. KG.
These funds have been invested as part of the capital increase resolved
in July 2011. Accordingly, dievini´s commitment to pay out the loan was
dissolved in full. At the end of the subscription period, 3,076,623 new
shares have been subscribed and thus the share capital increased from
EUR13,752,881 to EUR16,829,504.
• Long term financial liabilities amounted to EUR8.0 million resulting
from a loan which is not due for repayment before 2015.

Significant events after the balance sheet date

• During the first quarter, the patient recruitment for the AXIS 2 Study
performed well. On 8 August 2011, the last patient was recruited and
SYGNIS thus completed the patient enrolment successfully.
• Within the KIBRA project SYGNIS has taken meaningful steps with regard to
the patent situation. The European Patent Office and the US Patent and
Trademark Office have now issued elementary KIBRA patents. Both Patent
Offices have thus realised their announcements of May 2011.

Outlook

SYGNIS confirms its expectations of a net loss and a liquidity
outflow of around EUR9 million for the current 2011/2012
fiscal year. Including the financial funds of EUR6.2 million from
the capital increase, SYGNIS is financed until the end of calendar
year 2012.

The key operational focus for the upcoming months is the analysis of
the AXIS 2 Study data. First substantial results are expected to be
available by the end of calendar year 2011. Dependent on these
results, the Company will then evaluate the options for any
further development of AX200 and take necessary measures. This
will include a possible out-licensing or the further development of
the project with its own resources.

Within the KIBRA project, SYGNIS will continue its screening
activities, with the first possible drug candidates expected to
be identified in the 2011 calendar year. These results should
enable SYGNIS to enter into a research partnership or to
further develop suitable drug candidates with its own
resources.

In addition the Company continues to evaluate opportunities to extend its
product pipeline through partnerships or strategic transactions.

|Key financial figures for the first quarter of fiscal year |
|2011/2012 ended June 30, 2011 and corresponding figures (IFRS) |
|Numbers in million euros |Q1 2011/2012 |Q1 2010/2011 |
|Revenues |0.1 |0.1 |
|Total expenses |2.2 |2.5 |
|EBIT |-2.1 |-2.4 |
|Net results for the period |-1.3 |-2.3 |
|Intangible assets |20.6 |21.8 |
|Liquidity at end of quarter |4.8 |13.1 |
|Equity |15.6 |27.7 |
|(equity ratio in %) |(52) |(69) |
|Long-term financial liabilities |8.0 |8.0 |
|Operating Cash Flow |-2.0 |-2.3 |

The report on the first quarter which ended on June 30, 2011 is
available at the SYGNIS webpage at www.sygnis.de.

About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg,
is a specialty pharmaceutical company listed in the Prime
Standard of the Frankfurt Stock Exchange. The Company is
focused on the research and development of innovative therapies for
the treatment of disorders of the Central Nervous System. SYGNIS´
core projects are currently Acute Stroke for which SYGNIS´ lead
clinical programme is AX200, as well as the preclinical
KIBRA-project for the treatment of different forms of dementia.
All these disorders are characterized by the fact that, as the
disease progresses, nerve cells are damaged and die. Although there
is great medical demand, there are currently no or only
inadequate treatment options available. Furthermore, a key element
of the sustainable value creation of the Company is the expansion
of the product pipeline, which will be secured through its own
developments as well as in-licensing and acquisitions.

For further information please contact:
SYGNIS Pharma AG:

|Dr. Franz-Werner Haas |
|Senior Vice President Operations |
|+49 (0) 6221 454 812 |
|franz-werner.haas@sygnis.de |

Media-Contact:
Julia Phillips
Financial Dynamics
Tel.: +44 (0) 20 7269 7187

### Disclaimer Some statements included in this press release,
relating neither to proven financial results nor other historical
data, should be viewed as forward- looking, i.e. not definite.
Such statements are mainly predictions of future results, trends,
plans or goals. These statements should not be considered to be
total guarantees since given their very nature they are subject to
known and unknown risks and imponderability and can be affected by
other factors as a consequence of which the actual results, plans
and goals of SYGNIS Pharma AG may deviate greatly from the
established conclusions or implied predictions contained in such
statements. SYGNIS does not undertake to publicly update or revise
these statements in the light of new information or future results
or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English